Higher-Dose Donepezil for Alzheimer's Disease
Author Information
Author(s): Marwan Sabbagh, Jeffrey Cummings
Primary Institution: Banner Sun Health Research Institute
Hypothesis
Can a higher dose of donepezil improve cognitive function in patients with moderate to severe Alzheimer's disease?
Conclusion
The study found that a 23 mg dose of donepezil significantly improved cognition in patients with moderate to severe Alzheimer's disease compared to the standard 10 mg dose.
Supporting Evidence
- The study involved over 1400 patients with moderate to severe Alzheimer's disease.
- Patients receiving donepezil 23 mg showed significant cognitive improvement compared to those on 10 mg.
- The higher dose was well tolerated with a safety profile typical of AChEIs.
Takeaway
This study shows that giving a higher dose of a medicine called donepezil can help people with more serious memory problems from Alzheimer's disease feel better.
Methodology
A 24-week randomized, double-blind clinical trial comparing donepezil 23 mg/d to 10 mg/d in patients with moderate to severe Alzheimer's disease.
Potential Biases
Potential bias due to the involvement of authors in advisory roles for pharmaceutical companies.
Limitations
The study primarily focused on short-term outcomes and may not reflect long-term effects of the higher dose.
Participant Demographics
Patients with moderate to severe Alzheimer's disease, with a baseline MMSE score of 0-20.
Statistical Information
P-Value
0.001
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website